

SUBJECT INDEX

A

- Acetaminophen, 130, 133, 135, 655, 657
 - toxicity, 130, 133, 135
- Acetic acid, 158
- Acetylcholine
 - parietal cell stimulation and, 279-80
- Acetylcholine receptor
 - nicotinic, 474
- Acetylenes
 - cytochrome P450 inhibition and, 30
- Activin, 242
- Adeyde dehydrogenase, 324
- Adenine nucleotides, 541-43
 - physiological effects of, 543
- Adenosine, 458-59, 519-20, 541, 581-602
 - antiinflammatory effects of, 458-59
 - therapeutic uses of, 599-601
 - coronary vasodilation, 600
 - narrow complex tachycardia diagnosis, 599
 - preconditioning, 600
 - supraventricular arrhythmias, 599
- Adenosine receptor
 - ligands, 592-96
 - subtype, 581-602
 - A₁, 583-85, 598-99
 - A_{2a}, 585-87
 - A_{2b}, 587
 - A₃, 588-91
 - structure, 582
- Adenosine triphosphate (ATP), 140-41, 258, 261-62
 - depletion of
 - mitochondrial dysfunction and, 140-41
- S-Adenosylmethionine (AdoMet), 67
- S-Adenosylmethionine decarboxylase (AdoMetDC), 55, 57, 62-63
 - inhibition of, 70-73
 - therapeutic applications, 73-74
- Adenylate cyclase, 612, 621-24
- Adenylate cyclase, 547-48, 555
- Adhesion
 - leukocyte-endothelial, 450-59
 - antiinflammatory agents and, 450-59
 - corticosteroids and, 450, 455-58
 - immunoglobulin superfamily of proteins and, 450
 - integrins and, 45
 - methotrexate and, 450, 456-59
 - NSAIDs and, 449-55
- Adrenergic receptors, 18-20
- Adrenocorticotropin (ACTH), 439
- Adrenoreceptors, 418-32
 - expression by cells in immune system, 423-25
 - intracellular signaling of
 - lymphocytes and, 431-32
- Adriamycin, 135, 140
- African sleeping sickness, 55, 67-68
- African trypanosomes, 93-120
 - antigenic variations, 93, 95, 118-19
 - controlled protein degradations of, 93, 113-14
 - glycolytic enzymes, 98
 - glycosomal functions of, 93, 98-99, 107
 - kinetoplast DNAs, 107
 - polyamine metabolism of, 93, 114-15
 - protein import of, 93
 - purine salvage enzymes of, 93, 116-18
 - RNA editing in, 100, 107
 - surface glycoproteins of, 93, 118
 - trans-splicing of RNAs, 93, 107, 112-13
 - trypanothione metabolism, 93, 105, 107
- African trypanosomiasis, 93-120
 - chemotherapy, potential targets, 107-20
 - glycolipid anchor for variant surface glycoprotein, 118-19
 - glycosomes, 107-12
 - polyamine metabolism, 114-15
 - protein degradation, 113-14
 - purine salvage, 116-18
 - RNA processing, 112-13
 - trypanothione metabolism, 115-16
 - chemotherapy, present, 93-101
 - eflornithine, 93, 95
 - melarsoprol, 95-96
 - pentamidine, 95-96, 99-101
 - suramin, 95-99
- Agatoxins, 713-28
- AIDS
 - dementia in
 - nitric oxide and, 221
 - 4-Alkyl-1,4-dihydropyridines, 32
 - Alkylamines, 33-34
 - Alloxan, 135, 140
 - Amiloride, 257, 259-61
 - Aminoalkylindoles, 614-16
 - α -Amino-3-hydroxy-4-methyl-5-isoxazolepropionic acid (AMPA), 466
- Amoxicillin, 278, 301
- Angiotensin, 242
- Angiotensin-converting enzyme (ACE), 679-80, 686-96
 - inhibition, 690-96
 - inhibitors, 679, 691-96
- Anticancer drugs
 - metallothioneins and, 636-49
 - acquired and intrinsic drug resistance and, 640
 - induction of, 638-40
- Antiestrogens
 - drug development program for new, 204-6
 - molecular mechanism for resistance to, 200-4
 - nonsteroidal, 195-96
 - tamoxifen, 195-206
- Antigenic variation, 93, 95, 118-19
- Antiinflammatory drugs, 449-59
 - corticosteroids, 450, 455-56
 - methotrexate, 450, 456-59
- Antineoplastic agents
 - metallothioneins, 643-44
- Antioxidant response element (ARE), 324-25
- Antioxidants
 - cardiac remodeling and, 520
 - metallothioneins, 635, 646-48
- Antithrombin III, 197
- Antitrypanosomal action
 - DFMO, 103-7
 - eflornithine and, 93, 95, 103-6
 - mechanisms of, 93, 95-97
 - melarsoprol, 95-96, 101-3
 - pentamidine, 95-96, 99-101
 - suramin, 95-99
- Antitrypanosomal chemotherapy
 - potential targets for, 107-20
 - glycolipid anchor for variant surface glycoprotein, 118-19
 - glycosomes, 107-12

- polyamine metabolism, 114-15
 protein metabolism, 114-15
 protein degradation, 113-14
 purine salvage, 116-18
 RNA processing, 112-13
 trypanotone metabolism, 115-16
- α_1 Antitrypsin, 263-64
- Antitumor agents
- AdoMet, 73-74
- DFMO, 68-69
- MGBG, 70, 74
- polyamine analogues, 57, 68-69, 79-83
- Arachidonyl ethanolamine amide, 616-18
- Arcaine, 471
- Arginine, 165, 167, 176-78, 182-85, 213-14, 218-21, 242, 465
- methyl, 214
- nitric oxide and biosynthesis of, 165, 167, 172, 213
- nitric oxide synthase inhibition and, 182-85
- nitric oxide synthase-catalyzed oxidation of, 176-78
- nitro-, 214, 218, 221
- Aromatic amines, 308
- Arsenazo III, 130-31
- Arthritis
- rheumatoid, 418, 438-39, 449-50, 456-59
- Artificial chromosomes, 271
- Arctaspis engaddensis*, 236
- Atrial natriuretic peptide (ANP), 531
- Aryl hydrocarbon receptor (AHR), 307-30
- cloning and structure of, 309-11
- ligand-binding domain of, 314-15
- protein regulation by, 324-27
- xenobiotic-responsive element of, 310, 317-24
- Aryl hydrocarbon receptor complex (AHRC), 307-30
- endogenous ligand for, 328
- genetics of, 311-14
- novel heterodimers of, 329-30
- nuclear translocation of, 329
- Aryl hydrocarbon receptor nuclear translocator protein (ARNT), 307-30
- cloning and structure of, 309-11
- novel heterodimers of, 329-30
- xenobiotic-response element of, 310, 317-24
- Arylquinolines, 27, 296-98
- Atherosclerosis, 522-23
- Autoimmune disease, 418, 438-39
- B
- B lymphoblastoid cells
- cytochrome P450 expression in, 380-81
- Bacillus Calmette Guerin, 169
- Baculovirus
- cytochromes P450 expression in, 369, 371, 379-80
- Basal transcriptional enhancer (BTE), 322
- Basic transcription element binding protein (BTEB), 322
- Basophils, 425-26
- Benzimidazole, 277, 290-96, 298, 300-1
- Biologically based dose-response model of risk assessment, 361
- Birth defects
- measurement of chemically induced mutations and, 145
- Bis(chlorethyl)-nitrosourea (BCNU), 82
- Bovine retractor penis inhibitory factor (BRPIF), 22-23
- Bradykinin, 687-96
- Breast cancer
- long-term tamoxifen therapy and, 195-98, 201-6
- Bromobenzene, 130
- Bronchoconstriction, 237
- tert*-Butylhydroperoxide (tBH), 130, 135, 140
- C
- α -Calcitonin-gene-related peptide, 249, 280
- Calcium channels
- antagonists, 707-8, 717-25
- analgesic potential of, 724-25
- antihypertensive potential of, 717
- ischemia, 719-21
- therapeutic potential of, 719-25
- voltage-sensitive, 707-28
- Calcium ionophore, 242
- Calcium-mediated toxic cell injury, 129-39
- chemicals involved in, 130
- evidence against causative role, 134-35, 138-39
- measurement of intracellular free calcium, 130-32
- arsenazo III uptake, 130-31
- isolated hepatocyte suspensions, 132
- phosphorylase α activity, 130
- quin-2, 131-32
- Calmodulin
- nitric oxide synthase and, 175, 180-81, 185
- cAMP (See Cyclic AMP)
- Cancer
- breast, 195-98, 201-6
- chemically induced mutations and, 145
- endometrial, 197-200
- liver, 198-200
- polyamine analogues for treatment of, 55, 64-65, 68-69, 79-82
- transgenic animal models of, 145-46, 150-52, 158-61
- (See also Carcinogenesis, Carcinogenicity, Hepatocarcinogenicity, Mutagenesis, Transgenic mutation systems)
- Cannabinoid compounds, 607-28
- biological activity of
- enantioselectivity of, 610
- hydrophobicity of alkyl chain, 610
- hydroxylation of C₉ substituent, 612
- orientation of C₉ substituent of, 610, 612
- phenolic hydroxyl constituent of, 612
- Cannabinoid receptor, 607-28
- analgesia, 624-26
- agonists, 609-19
- antagonists, 619-20
- CB1 subtype, 608, 623-24
- regulation of ion channels, 623-24
- CB2 subtype, 608-9, 620-24
- coupling to effector systems, 624
- cognition and memory and, 626
- endocrine actions of, 627
- as G protein-coupled receptors, 621-24
- locomotor function and, 626-27
- Captopril, 249
- Carbon monoxide (CO), 213, 215
- as neurotransmitter, 213
- Carbon tetrachloride, 130
- Carcinogenesis
- chemically induced
- transgenic animal models of, 145-46, 150-52, 158-61
- nongenotoxic, 158-60
- ornithine decarboxylase over-expression and, 64-65

- polyamine accumulation and, 56
 (See also Cancer, Carcinogenicity, Hepatocarcinogenicity, Mutagenesis, Transgenic mutation systems)
- Carcinogenicity
 molecular biology of, 358-60
 risk assessment, 344, 355-60
 (See also Cancer, Carcinogenesis, Hepatocarcinogenicity, Mutagenesis, Transgenic mutation systems)
- Carcinoma
 endometrial
 tamoxifen and, 195
 lobular
 in situ, 197-98
- Cardiac muscle
 contractility of
 cardiac glycosides and, 14
 factors influencing, 13-14
 intracellular calcium concentration and, 14
 norepinephrine and, 14
 ryanodine and, 14
- Cardiac remodeling, 509-20
 adenosine and, 519-20
 α adrenoreceptors and, 516-17
 antioxidants and, 520
 fibroblast growth factor and, 516
 insulin-like growth factor and, 516
 ischemia and, 514
 mechanical overload and, 513-14
 renin-angiotensin system and, 517-19
 transforming growth factor- β and, 515-16
- Cardioprotection
 kinins and, 695
- Catecholamine, 238, 425-40
 activation of neutrophils, basophils, and mast cells, 425-26
 aging and, 436-38
 cytokine production and, 428-29
 immune system and, 425-40
 lymphocyte modulation by, 426-27
 lytic activity and, 428
 cDNA expression, 369-83
- Cell death
 anticancer drug-mediated, 636-46
 metallothioneins and, 635-46
- Cell injury
 calcium-mediated, 129-39
 chemicals involved in, 130
 chemically induced, 129-41
 oxidative
 calcium and, 129-39
 characteristics of, 133-34
 mitochondrial lesions and, 129, 139-41
- Cell proliferation
 abnormal, 64-65, 68-70, 150
 DFMO as antitumor agent, 68-69
 mutations and, 150
 polyamines and, 56, 64-65
- Chemical toxicity
 calcium and, 129-39
- Chicken ovalbumin upstream promoter transcription factor, 489
- Cholecystikinin-B receptor, 279
- Chloramphenicol, 35-36, 38-40
- Chloramphenicol acetyl transferase (CAT), 317
- Chloramphenicol acyltransferase (CAT), 111
- Chloride secretion, 257-63, 266-71
 cAMP-regulated, 257
 cystic fibrosis and, 257-63, 266-71
 gene therapy for, 266-71
- Chloroform, 130
- Cholinergic (ACh) neurotransmitter system
 effects of low-level lead exposure on, 392, 399, 405-9
- Chromatin structure
 polyamines as modulators of, 57
- Circulatory shock
 vasoactive factors in, 7-8
- Citrulline, 213
- Clarithromycin, 278
- Clofibrate, 485, 490, 493, 496
- Conopeptides, 710-28
- Conotoxins, 710-28
 neuronal voltage-sensitive calcium channels and, 710-28
- Corticosteroids, 450, 455-56
- Corticotropin-releasing factor (CRF), 439
- COS cells
 cytochrome P450 expression in, 377-78
- Cyclic AMP, 257, 423-26
 chloride secretion regulation and, 257
- Cyclic AMP-dependent protein kinase A (PKA), 258
- Cyclin-dependent kinases, 354, 359
- Cyclins, 354, 359
- Cycloalkylamines, 32
- Cystamine, 130
- Cystic fibrosis, 257-71
 cAMP-regulated chloride secretion and, 257-58
 ATP and, 258
 PKA and, 258
 control of inflammation
 α_1 antitrypsin and, 263-64
 α_1 proteinase inhibitor and, 264
 corticosteroids and, 264-65
 NSAIDs and, 265
 secretory leukocyte protease inhibitors and, 264
 gene therapy for, 266-71
 artificial chromosomes, 271
 liposomal-mediated, 270
 viral vectors for, 267-70
 increase in chloride secretion, 261-62
 adenosine triphosphate and, 261-62
 nucleotidyl triphosphates and, 261-62
 uridine triphosphate and, 261-62
 in vivo gene therapy for, 257
 mutations in CF transmembrane regulator, 257
 new therapies for, 258-71
 protein replacement therapy, 265-66
 reduction for mucus viscosity
 deoxyribonucleases and, 262-63
 gelatin and, 263
 reduction of sodium absorption and, 259-61
 amiloride and, 259-61
- Cystic fibrosis transmembrane regulator (CFTR)
 adenosine triphosphate and, 258
 cAMP-dependent protein kinase A and, 258
 gene therapy, 266-71
 protein replacement therapy, 265-66
- Cytochrome b₅, 370, 377, 379-80
- Cytochrome P450, 29-47, 177, 215, 299, 308, 369-83
 aromatase, 383
 bacterial expression systems, 369-74
 catalytic activities, 30-31
 catalytic mechanisms, 32
 inhibition
 acetylenes, 30
 mechanisms of, 32-36
 olefins, 30
 structural basis of, 44-47
 inhibitors
 identifying, 39-41

- selectivity, 36-39
insect expression systems of, 369, 379-80
baculovirus, 379-80
B-lymphoblastoid cells, 380-81
mammalian expression systems, 369, 377-79
COS cells, 377-78
vaccinia, 378-79
mechanism-based inactivation of, 31-32, 34-36
oxygen transfer by, 32
polycyclic aromatic hydrocarbon metabolism and, 308
retrovirus, 381
site-directed mutagenesis studies of, 41-44
substrate specificity of, 29-31, 41-47
enzymatic determinants of, 29
structural basis of, 41-47
use of inhibitors for determining, 31
xenobiotic metabolism and, 29
yeast expression systems, 369, 371, 374-77
Cytochrome P450 reductase, 215
Cytokines, 417, 428-29, 655, 664-66, 684
catecholamines and, 428-29
tissue injury and, 655, 664-66
role of macrophages in, 664-66
Cytotoxic T lymphocytes (CTL), 350
- D**
- D1 receptor
low-level lead exposure and, 398-402, 409
D2 receptor
low-level lead exposure and, 398-402, 409
Decarboxylated S-adenosylmethionine (dcAdoMet), 57
Delayed hypersensitivity response, 350
Delayed type hypersensitivity, 434
Deoxyribonuclease (DNase), 257, 262-63
DFMO, 59, 65-83, 103-7
antitrypanosomal action of, 103-7
contragestational property of, 69-70
therapeutic uses of, 67-70, 103-7
antiparasitic, 67-68, 103-7
antitumor, 68-69
chemoprevention, 69
toxicity of, 70
Diabetes
potential therapeutic effect of kinins, 693
Diaminobutane, 464
Diethyldithiocarbamate, 39
Diethylenetriamine (DET), 471-73, 476
Diethylnitrosamine (DEN), 151-52, 159
DL- α -Difluoromethylornithin (See DFMO)
Digital imaging fluorescence microscopy, 129, 132, 134-35
Dihydroxyphenylacetic acid (DOPAC), 398, 440
Dimethylnitrosamine (DMN), 150-52
Diminazene, 95, 106-7
Dioxin, 307-30, 346 (See also TCDD)
Dizocilpine, 402
Dopaminergic (DA) neurotransmitter system
effects of low-level exposure to lead, 392, 398-402, 407-9
Droloxifene, 205
Drug metabolism
mechanism-based cytochrome P450 inhibitors and, 31-32, 34-36
structure-based cytochrome P450 inhibitors and, 30
Duodenum ulcer disease (See Ulcer disease)
- E**
- Ectonucleotidases, 542
EDRF (See Endothelium-derived relaxing factor, Nitric oxide)
Efornithine, 93, 95-96
EGTA, 139
Eicosanoids, 616-18, 663-64
Ellipticines, 33
Endometrial cancer
tamoxifen and, 197-200
Endothelin, 235-50, 684
isoforms of, 236
presynaptic neuromodulatory effect of, 241
shear stress and, 242
in vascular beds, 242-44
vasoconstriction and, 235, 237-50
vasodilation and, 235-50
Endothelin-converting enzyme (ECE), 239, 243-44, 247
Endothelium, 679-96
transduction mechanisms in cells of, 687-89
vasoconstriction and, 679-80
vasodilation and, 679-80
Endothelium-derived hyperpolarizing factor, 682-83
Endothelium-derived mediators
cytokines, 417, 428-29, 655, 664-66, 684
endothelin, 235-50, 684
endothelium-derived hyperpolarizing factor, 682-83
growth factors, 324, 515-16, 524, 664-66, 684
nitric oxide, 1, 20-24, 165-86, 213-26, 235, 239, 242, 248-49, 525-26, 655-56, 680-81, 684, 688-90
oxygen reactive metabolites, 682, 693
platelet-activating factor, 682-84
prostaglandins, 451-54, 681-82
Endothelium-derived relaxing factor (EDRF), 1, 13, 20-24, 167-68, 170, 214
discovery of, 20-24
Enterochromaffin-like cell, 279
Enzyme replacement
pancreatic, 257
Enzymology
of nitric oxide synthases, 165-66, 172-86
Epinephrine, 423
Epithelial cells
cAMP-regulated chlorine secretion of, 257-63, 266-71
cystic fibrosis and, 257-71
Erythrocyte membranes, 1, 4
Erythrocytes
electrophoretic mobility of, 4
shape changes in, 4
Escherichia coli
lacI of, 145-47, 149, 151, 153-60
lacZ of, 145-47, 149, 151, 153-56
Estradiol, 204
Estrogen, 196, 201, 203-4
receptors, 203-4
7-Ethoxycoumarin, 38
7-Ethoxyresorufin-O-deethylase, 37
Ethylene glycol-bis(β -aminoethyl ether) (EGTA), 139
Ethyl nitrosourea (ENU), 151-52
- F**
- Ferritin, 8
Fibroblast growth factor, 516, 524
Fibrogen, 197

Fixed-Interval schedule operant behavior, 391, 402, 407-9
 low-level lead exposure and changes in DA system, 402, 407-9
 Flavin adenine dinucleotide (FAD), 215
 Flavin mononucleotide, 215
 Flavoprotein function
 nitric oxide synthase and, 179-80
 Free radicals
 protective role of metallothioneins against, 635, 646-48
 Furfurylline, 39
 G
 Gamma-butyrolactone, 398
 Gastric acid pump (See H^+, K^+ ATPase)
 Gastric secretion, 277-301
 acid-related disease, 278
 regulation of, 279-80
 therapeutic control of, 278, 292-301
 (See also H^+, K^+ ATPase)
 Gastric ulcer disease (See Ulcer disease)
 Gelsolin, 263
 Gene rescue techniques, 153-54
 lambda phage systems, 153-54
 plasmid-based systems, 154
 Gene therapy
 cystic fibrosis and, 257, 266-71
 Genotoxicity, 145, 150-52, 157
 Gestodene, 39
 Ghosts
 erythrocyte, 4, 5
Glossina, 93
 Glutamate neurotoxicity
 nitric oxide and, 171
 Glutamergic (GLU) neurotransmitter system
 effects of low-level lead exposure on, 392, 399, 402-5, 407-9
 Glycosomes, 93, 98-99, 107-12
 as potential target for antitrypanosomal chemotherapy, 107-12
 G protein-coupled receptors, 581-602, 621-24, 687-89, 694
 cannabinoid receptors as, 621-24
 desensitization, 596-98
 G protein-linked receptors
 P_2 -purinergic receptors, 541-71
 Guide RNAs, 100

H
 H^+, K^+ ATPase, 277-301
 biosynthesis of, 285-86
 catalytic cycle of, 287-89
 inhibitors
 lansoprazole, 277-78, 292-96, 298-99
 omeprazole, 277-78, 284, 292-96, 298-300
 pantoprazole, 277-78, 293-96, 298-99
 membrane assembly and targeting of, 286-87
 structure of, 280-85
 therapeutic control of, 278, 292-301
 side effects, 292-301
Haemophilus influenza, 258
 Halogenated aromatic hydrocarbons (HAHs), 307-30
 pathways of pathogenesis, 307
Helicobacter pylori, 278, 298, 300-1
 duodenal and gastric ulcer disease and
 benzimidazole treatment of, 300-1
 Heme
 binding agents
 nitric oxide synthase inhibition and, 181-82
 nitric oxide and, 224
 proteins, 681
 Hemoglobin, 167
 Hemorrhage
 subarachnoid
 kinins and, 695-96
 Heparin, 530
 Hepatocarcinogenicity, 483-50
 mechanisms of, 483, 488-96
 cell replication, 483, 494-95, 499
 oxidative stress, 483, 491-94
 promotion of lesions, 483, 495-96
 (See also Liver tumor formation, Peroxisomes)
 Hepatocytes, 134
 Heptachlor, 158
 Homeobox genes, 512
 Homidum, 95, 106-7
 Homovanillic acid (HVA), 398
 Human adenovirus neutralizing antibody (HAN), 268
 Hydrazines, 33
 6-Hydroxydopamine (6-OHDA), 422, 433, 438
 5-Hydroxytryptamine (5-HT), 248
 Hypertension, 167, 237-38, 521-22, 692

kinins
 potential therapeutic effect of, 692
 pathogenesis of, 238
 catecholamines and, 238
 renin-angiotensin system and, 238
 Hypusine, 62
 I
 ICI, 182,780, 205
 Imidazoles, 33
 Imidazopyridines, 296
 Immune system, 169-70, 417-41
 adrenoreceptors and, 418-32
 aging and, 436-38
 catecholamine and, 425-40
 cytokine production and, 428-29
 lytic activity and, 428
 modulation of lymphocytes by, 426-27
 modulation of sympathetic activity by, 440-41
 nitric oxide's role in, 169-70
 Inflammation
 macrophage activation and, 655-96
 cytokines and, 664-66
 eicosanoids and, 663-64
 growth factors and, 664-66
 hydrolytic enzymes and, 664
 reactive oxygen and, 661-63
 Inositol lipid hydrolysis, 546-47
 Inositol 1,4,5-trisphosphate (IP₃), 246, 250
 endothelin-1-induced vasoconstriction and, 246, 250
 Insulin, 242
 Interferon- γ , 169
 Interleukin-1, 451
 Iron regulatory factors, 222
 Iron-responsive elements, 222
 Isoform-selective chemical inhibitors, 30, 37-47
 Isometamidium, 95, 106-7
 Isoproterenol, 423
 K
 Kaicic acid, 466
 Keoxifene (See Raloxifene)
 Ketoconazole, 33
 Kinins
 angiotensin-converting enzyme, 679-80, 686-96
 inhibitors and, 679
 blood pressure regulation and, 689
 cardiovascular disease and, 691-92

- potential therapeutic benefits
of, 692-96
atherosclerosis and, 694-95
cardioprotection and, 695
diabetes and, 693
hypertension and, 692
subarachnoid hemorrhage
and, 695-96
potentiation of, 692
receptors, 687-89
regional blood flow and, 689-90
septic shock and, 690-91
vascular metabolism of, 684-87
kininases, 686-87
kininogenases, 685-86
kininogens, 685, 690
Kininases, 686-87
Kininogenases, 685, 86
Kininogens, 685, 690
- L**
- lacI*, 145-47, 149, 151, 153-60
lacZ, 145-47, 149, 151, 153-56
Lambert-Eaton myasthenic syndrome, 725-26
Lansoprazole, 277-78, 292-96, 298-99
- Lead exposure
auditory and visual system deficits from, 397
changes in reaction time from, 397
chelation therapy for, 393
cholinergic system changes from, 392, 399, 405-9
dopaminergic system impairments from, 391, 398-402, 407-9
Fixed-Interval schedules and, 391, 402, 407-9
glutamatergic system changes from, 392, 399, 402-5, 407-9
learning impairments from, 391-409
low-level, 391-409
NMDA receptor complex and inhibitory effects on, 391
- Learning
impairments from lead exposure, 391-409
nitric oxide and, 219
- Leishmaniasis
antimony-resistant, 99
- Leukocyte-endothelial interactions, 450-59
- Ligand binding, 592-96
- Ligation-mediated polymerase chain reaction, 317-18
- Lipopolysaccharide, 216-17, 426-27, 451, 667
- sepsis and, 217
tumor necrosis factor- β and, 428-29
- Liver**
cancer, 198-200
damage
calcium accumulation and, 130
hepatotoxicity
macrophages and, 660-61
tissue injury in, 655-56
- Liver tumor formation**
mechanisms of
cell replication, 483, 494-95, 499
oxidative stress, 483, 491-94
promotion of lesions, 483, 495-96
species differences in, 496-98
(See also Hepatocarcinogenicity, Peroxisomes)
- Lobular carcinoma in situ, 197-98
- Long-term potentiation, 219, 403
- nitric oxide and, 219
- Lowest observed effect level (LOEL), 344, 347
- Lung**
pulmonary toxicity
macrophages and, 657-60
tissue injury in, 655-56
- Lymphocytes, 417-32
activation of, 424
 β -adrenoreceptor density among, 423-24
catecholamine-induced modulation of, 426-27
cytotoxic, 430
intracellular signaling of, 431-32
adrenoreceptor-mediated mechanisms and, 431-32
- Lymphoid organs
noradrenergic innervation of, 418-23
- Lymphokine-activated killer cells, 429
- M**
- Macrophages, 655-96
hepatotoxicity and, 660-61
proinflammatory mediators released by, 661-66
cytokines, 664-66
eicosanoids, 663-64
growth factors, 664-66
hydrolytic enzymes, 664
reactive oxygen, 661-63
pulmonary toxicity and, 657-60
- tissue injury and, 655-96
model for, 667-69
- Major histocompatibility complex (MHC), 427
- Mast cells, 425-26
- Medulla oblongata, 241
- Melarsen-trypanothione adduct, 102
- Melarsoprol, 95-96, 101-3
antitrypanosomal action of, 103
resistance to, 102
- Memory
nitric oxide and, 219
- Menadione, 130, 135, 140
- Metabolic inhibitors
sites of action of, 9
- Metabolism, 5, 8, 10
drug
mechanism-based cytochrome P450 inactivators and, 31-32, 34-36
structure-based cytochrome P450 inhibitors and, 30
oxidative energy, 5, 8-9
rabbit intestinal smooth muscle, 8-10
xenobiotic, 29-30
- Metallothioneins, 635-49
antineoplastic properties of, 643-46
antioxidant properties of, 635, 646-48
biology of cell death and, 635-46
gene transfer studies, 638-40
induction mechanisms of, 638-40
protection against electrophilic anticancer drugs, 636-46
- Methotrexate, 450, 456-59
adenosine and, 458-59
(2R, 5R)- δ -Methyl-acetylenic putrescine (MAP), 66-67
- Methylene blue, 167
- Methylenedioxycocaine, 33-34
- Methylmethane sulfonate (MMS), 150, 157, 159
- Mitochondria
calcium cycling in, 139-40
oxidative cell injury and, 129, 139-41
ATP depletion and, 340-41
calcium ions and, 139-41
Mixed lymphocyte response, 350
- Mosaic plaque techniques, 155
- Mutagenesis, 145-61
diethylnitrosamine-induced, 150-51, 157, 159
ethylnitrosamine-induced, 151-52, 157
methylmethane sulfonate-induced, 150, 157, 159

- by nongenotoxic carcinogens, 158-50
 target genes for, 147-49
 transgenic mutation systems and, 147-49
 (See also Carcinogenesis, Transgenic mutation systems)
- Mutations
 cell proliferation and, 150
 chemically induced, 145, 150-52, 157
 deletion, 157-58
 measurement of, 145-61
 Myocardial ischemia, 138
- N
- NADPH-P450 oxidoreductase, 370, 379
 Nagana, 93
 National Surgical Adjuvant Breast Project, 198
 Natural killer cell activity, 350
 Neuronal cells
 hypoxic injury to, 138
 Neurotoxicity
 nitric oxide as mediator of, 221-26
 glutamate and, 221
 Neutrophils, 425-26
 N-Hydroxy-L-arginine, 177
 Nicotinic acetylcholine receptor, 474
 Nitric oxide (NO), 1, 20-24, 165-86, 213-26, 235, 239, 242, 248-49, 525-26, 655-56, 680-81, 684, 688-90
 biosynthesis of, 213-26, 165-86
 arginine and, 165, 167, 172, 213
 calmodulin and, 213
 citrulline and, 213
 nitric oxide synthases and, 166-86, 213
 in central nervous system, 170
 as cytotoxic agent, 169-71
 glutamate neurotoxicity and, 171
 as endothelium-derived relaxing factor, 167
 learning and memory and, 219
 long-term potentiation and, 219
 immune system and, 169-70
 inhibition of platelet aggregation, 168-69
 manipulation of, 166
 as mediator of neurotoxicity, 221-26
 AIDS dementia and, 221
 poly(ADP-ribose) synthesis and, 225-26
 S-nitrosylation and, 224
 in neural development, 217-21
 as neurotransmitter, 167, 170-71, 213-26
 in peripheral nervous system, 170
 in signal transduction, 167, 170-71, 213-26
 tissue injury and, 655-56
 vascular system and, 167-68, 213
 vascular tone and, 235, 239, 242, 248-49
 vasorelaxation and, 167-68
 Nitric oxide synthase, 165-86, 213-21
 constitutive, 173-76, 178-86, 216
 endothelial (eNOS), 215
 enzymology of, 165-66, 172-86
 inducible, 173-76, 178-86, 216
 isoforms of, 165-66
 macrophage form (mNOS), 215
 neuronal (nNOS), 214, 218-21
 regulation of, 175-76
 selective inhibition of, 165-66, 176-86
 arginine analogs and, 182-85
 calmodulin function and, 180-81
 flavoprotein function and, 179-80
 H₄ biosynthesis and, 182
 heme-binding agents and, 181-82
 nitrogen-containing compounds, 182
 thiol function and, 180
 in spinal cord, 216
 Nitrogen heterocycles, 33
 Nitroglycerin, 214
 NMDA (See *N*-methyl-D-aspartate)
N-methyl-D-aspartate (NMDA), 170, 213-14, 218, 221-22
N-methyl-D-aspartate receptor channels, 463-77
 characterization of, 469-70
 molecular biology of, 473-75
 polyamine binding site on, 471
 polyamine interaction with, 463-69, 471-77
 regulatory sites on, 470-71
N-methyl-D-aspartate receptor complex
 long-term potentiation and, 403
 low-level lead exposure and, 391, 402-5, 407-9
 glutamatergic system changes and, 402-5, 407-9
 inhibitory effects of, 391
 N-methyl-L-arginine, 167, 183-85
 N^G-monomethyl-L-arginine, 239
 N-nitro-L-arginine, 184-85
 Nonadrenergic, noncholinergic neurons, 170-71
 Nonadrenergic, noncholinergic neurotransmitter, 22-23
 Nonsteroidal antiinflammatory drugs (NSAIDs), 265, 449-55
 biochemical mechanism of, 454-55
 neutrophil functions and, 454
 prostaglandins and, 451-53
 No observed effect level (NOEL), 344
 Noradrenergic innervation of lymphoid organs, 417-23
 lymph nodes, 418
 spleen, 448
 Norepinephrine, 248, 418
 immune responsiveness and, 418
 Nucleotide triphosphate, 261-62
 Nucleus accumbens
 low-level lead exposure and, 398-402
- O
- 6-OHDA (See 6-Hydroxydopamine)
 Olefins
 cytochrome P450 inhibition and, 30, 32
 Omeprazole, 277-78, 284, 292-96, 298-300
 Ornithine decarboxylase (ODC), 55-57, 62-67, 93, 96, 103-4, 464-66
 biosynthesis of polyamines and, 103
 inhibition of, 65-67
 DFMO and, 65-67
 MAP and, 66-67
 overexpression of malignant transformation and, 64-65
 Overdose poisoning, 129
 Oxidative energy metabolism, 5
 Oxidative stress, 130-41, 483, 491-94, 635, 646-48
 calcium-translocating enzyme systems and, 132-33
 influx of extracellular calcium and, 133
 intracellular calcium release and, 133
 liver tumor promotion and, 483, 491-94
 mitochondrial dysfunction and, 139-41
 models of, 130, 135

- Oxotremorine, 406
 Oxygen reactive metabolites, 682, 693
- P**
- Pancreatic enzyme replacement, 257
 Pantaprazole, 277-78, 293-96, 298-99
 Parasitic diseases, 55, 67-68, 73-74
 Parietal cell, 278-80, 289-91
 gastric secretion regulation and, 278-80, 289-91
 acetylcholine and, 279-80
 Parkinson's disease, 398
 Pentamidine, 95-96, 99-101
 antitrypanosomal action of, 95-96, 99-101
 molecular conformation of, 99
 Peripheral adrenergic mechanisms, 12, 15-17
 Peroxisome proliferator-activated receptors (PPAR), 488-90
 Peroxisomes, 483-500
 hepatic proliferation of, 483-500
 assessment of, 486-88
 characteristics of, 485
 in vitro, 488
 peroxisome proliferators as substrates for peroxisomal enzyme hypothesis, 488-90
 receptor hypothesis of, 488-90
 substrate overload hypothesis of, 488-90
 structure of rodent liver peroxisome proliferators, 484, 486
 (See also Hepatocarcinogenicity, Liver tumor formation)
- Pertussis toxin, 455, 584, 600
 p53 tumor suppressor gene, 359-60
 Phenobarbital, 159
 Phenylcyclidine, 39, 402
 Phorbol myristate acid (PMA), 425
 Phospholipase C (PLC), 246, 250, 544, 547, 549
 endothelin-1-induced vasoconstriction and, 246, 250
 Phosphorylase α , 131, 135
 Photorelaxation
 of blood vessels, 11-13
 discovery of, 11
 potentiation by sodium nitrite, 13
- Physiologically based pharmacokinetic models of risk assessment, 361
 Plasminogen activator inhibitor, 324
 Platelet-derived growth factor, 524
 Platelets
 nitric oxide and, 168-69
 Poly(ADP-ribose) synthetase (PARS), 225-26
 Polyamine analogues
 antitumor potential of, 68-69
 BE-3-3-3, 80-81
 BE-3-7-3, 80-81
 BE-4-4-4-4, 81-82
 cancer treatment with, 55, 68-69, 79-82
 synthesis of, 56-57
 antitumor agents from, 57
 Polyamine oxidase, 63, 69
 Polyamines, 55-83, 93, 103-6, 114-15, 463-77
 biosynthesis of, 103-6
 cell proliferation and, 56
 chromatin structure and modulation of, 57
 inhibitors of, 57-63
 interaction with DNA, 77-79
 metabolism, 93, 114-15
 NMDA receptor channel regulation and, 463-77
 putrescine, 103-4
 spermidine, 57, 59, 62, 77, 79-80, 103-5, 114, 464-66, 468-69, 472-73
 spermine, 57, 59, 62, 77, 79-80, 103-4, 464-66, 468-69, 472-73, 476
 synthesis of, 57-63
 Polyamine transport, 74-79
 polyamine-DNA interactions and, 77-79
 up-regulation of polyamine depletion and, 75-76
 Polyaromatic hydrocarbons (PAHs), 346
 Polychlorinated biphenyls (PCBs), 346
 Polycyclic aromatic hydrocarbons (PAHs), 307-30
 cytochrome P450 metabolism of, 308
 Potassium cyanide, 132, 134
 P₂-purinergic receptors, 541-71
 agonists, 560-63
 radioligand-binding assays for, 563-66
 structure, 566-70
 subtypes, 545-59
- Pravadoline, 614-16
 Preconditioning
 adenosine treatment for, 600
 Prostacycline, 235, 249
 Prostaglandins, 451-54, 681-82
 Protein kinase
 cAMP-dependent, 258
 Protein kinase C (PKC), 432, 585, 601
 Protein replacement therapy, 265
 α_1 -Proteinase inhibitor, 264
 Proton-pump inhibitors, 277
Pseudomonas, 258
 Putrescine, 57, 59, 64, 79-80, 103-4, 464-66
 Pyridines, 33
 2-Pyridyl methylsulfenyl benzimidazole, 277, 290-94, 298
- Q**
- Quinidine, 39
 Quinolines, 33
 Quinoxalinediones, 466
 Quin-2, 131-32, 139
- R**
- Raloxifene, 205-6
 Ranitidine, 285, 301
 Reactive oxygen intermediates
 tissue injury and, 655, 661
 Receptor theory, 10-12, 17-20
 Recombinant adreno-associated virus, 269
 Reference dose, 344
 Remodeling (See Cardiac remodeling, Vascular remodeling; see also Renin-angiotensin system)
 Renin-angiotensin system, 238, 249, 250, 517-19, 528-29, 691-92
 cardiovascular remodeling and, 517-19
 angiotensin II and, 528-29
 increased extracellular matrix collagen and, 518-19
 myocyte hypertrophy and, 517
 ventricular dilation and, 517-18
 Reperfusion injury, 138
 Restinosis, 523-24
 Retinoid X receptor, 489
 Retrovirus
 cytochrome P450 expression in, 381-82
 Risk assessment, 341-63
 animal-to-human extrapolation, 344-45

- carcinogenicity, 344, 355-60
- developmental toxicity, 352-54
- dose-response assessment, 341-43, 360-63
- dose-response extrapolation, 344
- exposure assessment, 342-43
- genotoxicity, 354-55
- hazard identification, 341, 343
- immunotoxicity, 349-52
- low-dose extrapolation for quantitative, 356-58
- modeling, 356-57, 360-63
 - biologically based dose-response model, 361
- neurotoxicity, 344, 346-49
- reference dose, 344
- reproductive toxicity, 352-54
- risk characterization, 342-43
- toxicokinetics, 360-63
- US EPA Integrated Risk Information System, 351
- (See also Toxicity)
- RNA editing, 100, 107, 112-13
- Rostro-ventrolateral medulla, 241
- RU 486, 439-40
- Ryanodine
 - calcium transport and, 14
 - contractility of cardiac muscle and, 14
- S
- Sarafotoxin, 236
- Sarcoplasmic and endoplasmic reticulum (SERCA), 281
- Secobarbital, 36
- Second-messenger signaling
 - G protein-linked, 543-45
 - P₂-purinergic receptors and, 543-45
- Septic shock
 - kinins and, 690-91
- Sepsis
 - lipopolysaccharide, 217
- Serine-lysine-leucine (SKL), 109, 111
- Shuttle-vector packaging reaction, 153
- Site-directed mutagenesis, 41-44, 595-96
 - cytochrome P450, 41-44
 - ligand binding of adenosine receptor, 595-96
- Sleeping sickness, 93
- Small nuclear ribonucleoprotein particles, 100
- Smooth muscle metabolism, 8-11
 - photorelaxation in, 11-12
 - receptor theory and, 10-12
- Snake venom
 - sarafotoxin, 236
- S-nitrosylation
 - nitric oxide and, 224
- Species differences
 - in hepatic peroxisome proliferation, 496-98
- Spermidine, 57, 59, 62, 77, 79-80, 103-5, 114, 464-66, 468-69, 472-73
- Spermidine-spermine N¹-acetyltransferase (SSAT), 57, 63
- Spermine, 57, 59, 62, 77, 79-80, 103-4, 464-66, 468-69, 472-73, 476
- Spider venom, 713-28
- Staphylococcus aureus*, 258
- Steroid hydroxylase assays, 37
- Steroid-thyroid retinoic acid receptor superfamily of proteins, 309
- Structure-activity relationships, 346
- Sulfaphenazole, 39
- Superoxide, 167
- Superoxide dismutase (SOD), 22-23
- Suramin, 95-99
 - analogues of, 97
 - antitrypanosomal action of mechanism of, 98-99
 - multi-action of, 97-98
 - therapeutic value of basis of, 97
- Synaptic transmission
 - carbon monoxide and, 213
 - nitric oxide and, 213-14
- T
- Tamoxifen, 195-206
 - breast cancer prevention and treatment with, 195-206
 - cholesterol levels and, 197
 - drug resistance, 200-4
 - high estrogen levels and, 201
 - liver carcinogenesis and, 198-200
 - long-term therapy with, 196
 - mammary tumorigenesis and, 196-98
 - mutated estrogen receptors and, 203-4
 - post-menopausal bone density and, 196
 - toxicities of, 198-200
- TATA box, 217, 322
- mutations in, 322
- TCDD, 308-30
 - mechanisms involved in pathogenic responses to, 330
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (See Dioxin, TCDD)
- Tetradecanoyl phorbol acetate, 323
- Δ^9 -Tetrahydrocannabinol (Δ^9 -THC), 607-28
 - (See also Cannabinoid compounds, Cannabinoid receptors)
- Thiol function
 - nitric oxide synthase and, 180
- Thrombin, 242
- Time-to-tumor models, 356
- Tissue injury
 - macrophages' role in, 655-96
 - model for, 667-69
 - xenobiotic-induced, 655
- Toremifene, 204-5
- Toxicity, 129-39, 341-63
 - animal-to-human extrapolation, 344
 - calcium ions and chemical, 129-39
 - dose-response extrapolation, 344
 - lowest observed effect level, 344
 - mechanisms of low-level, 343
 - no observed effect level, 345
 - overdose poisoning and, 129
 - reference dose, 344
 - risk assessment, 341-63
 - (See also Risk assessment)
- Toxicity equivalent factors, 346
 - for dioxin, 346
- Transforming growth factor, 324
- Transforming growth factor- β (TGF- β), 242
- Transgenic animals, 145-61
 - measuring mutations, 145-61
 - methods for producing, 146
 - multiple, 160
 - (See also Transgenic mutation systems)
- Transgenic mutation systems, 146-61
 - color screening of mutants, 154-56
 - DNA isolation, 152
 - dose selection, 150
 - dosing regimen, 149-50
 - fixation time, 151-52
 - gene rescue techniques, 153-54
 - methods of analysis, 156-58
 - mosaic plaque assay, 155
 - mutation spectra, 156-58
 - plating conditions, 155
 - selectable systems, 155-56
 - target genes for, 147-49
- Triacetyloleadomycin, 39
- Tricarboxylic acid, 94
- Trypanosoma* (See African trypanosomes)
- Trypanothione, 93, 105, 107, 115-16
 - metabolism, 115-16

- Tsetse
African trypanosomiasis from, 93-120
(See also African trypanosomes, African trypanosomiasis)
- Tumor necrosis factor- α , 242, 524
- Tumor promotion
liver
enhanced cell replication and, 483, 494-95, 499
oxidative stress and, 483, 491-94
promotion of spontaneous preneoplastic lesions, 483, 495-96
species differences in, 496-98
- Tumorigenesis
mammary
tamifen and, 196-98
- Tyrosine hydroxylase (TH), 398, 420, 424, 441
- U
- Ulcer disease
duodenum, 278, 298, 300-1
gastric, 278, 300-1
noniatrogenic, 278, 300-1
Helicobacter pylori infection and, 278, 298, 300-1
therapy for, 300-1
- Unscheduled DNA synthesis, 159
- Uridine, 545
- Uridine triphosphate, 257, 261-62, 271
- Urokinase-type plasminogen activator, 529-30
- US EPA Integrated Risk Information System, 351
- V
- Vaccinia virus
cytochrome P450 expression in, 378
- Vagus nerve, 279
- Variant surface glycoprotein (VSG), 94-95, 118-19
antigenic variation of, 95, 118-19
- Vascular endothelial growth factor, 524-25
- Vascular kallikrein-kinin system (See Kinins)
- Vascular remodeling, 509-12, 520-31
antihypertensive drugs and, 526-27
in atherosclerosis, 522-23
endothelium-derived vasoactive substances, 525-26
nitric oxide, 525-26
prostacyclin, 525
TGF- β , 525-26
in hypertension, 521-22
polypeptides and, 524-25
restinosis and, 523-24
thrombin and, 529
urokinase-type plasminogen inhibitor and, 529-30
atrial natriuretic peptide, 531
heparin, 530
- Vascular smooth muscle
endothelial control of, 679-96
- Vascular smooth muscle cells, 511, 520-31
angiotensin II and, 528-29
hyperplasia of, 521
(See also Vascular remodeling)
- Vascular tone
role of endothelin in, 235-50
- Vasoactive intestinal polypeptide (VIP), 219
- Vasodepressor material, 7-8
circulatory shock and, 7-8
hypertension and, 8
- Vasorelaxatory material (VEM), 7-8
circulatory shock and, 7-8
hypertension and, 8
- Vasoconstriction
endothelin-1-induced, 235-50
cytosolic IP₃ production and, 246, 250
phospholipid C stimulation and, 246, 250
- Vasodilation
endothelin-1 and, 235-50
- Vasorelaxation
EDRF-elicited, 167-68
nitric oxide and, 167-68
vasorelaxing factor and, 242
- Vasorelaxing factor, 242
- Vasospasm, 237-38
- X
- Xenobiotic metabolism
hepatic
gene families responsible for, 29-30
- Xenobiotic responsive element (XRE), 310, 317-25, 330
- Xenobiotics
tissue injury and, 655-96
- Y
- Yeast
cytochrome P450 expression in, 369, 371, 374-77

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 31-35

A

Alemà S, 31:205-28
Amidon GL, 34:321-41
Andersen ME, 31:503-23
Angle CR, 33:409-33

B

Bathon JM, 31:129-62
Bellomo G, 32:449-70
Bertolino M, 32:399-421
Bessis A, 31:37-72
Bevan JA, 34:173-90
Birnbbaum LS, 31:101-28
Blumer JL, 31:525-47
Bowery NG, 33:109-47
Boyer JL, 35:541-79
Brater DC, 33:435-65
Bray TM, 34:91-115
Briving C, 35:277-305
Bunzow JR, 33:281-307
Burch RM, 32:511-36

C

Caron MG, 32:167-83
Chan P-C, 34:41-67
Chang LW, 34:41-67
Changeux J-P, 31:37-72
Chao AC, 35:257-76
Chaudhuri G, 35:165-94
Chen AY, 34:191-218
Chiou GCY, 31:457-67
Chiu AT, 32:135-65
Civelli O, 33:281-307
Claghorn JL, 33:165-77
Clarkson TW, 33:545-71
Cohen AJ, 31:253-87
Conolly RB, 31:503-23
Cordell B, 34:69-89
Corey JL, 34:219-49
Cory-Slechta DA, 35:391-415
Costa M, 31:321-37
Cronstein BN, 35:449-62
Crooke ST, 32:329-76

D

Dahl AR, 33:383-407
Davis B, 35:341-68
Delzenne N, 31:163-75

De Mey JGR, 35:501-39
de Montellano PRO, 32:89-107
Dubocovich ML, 31:549-68

E

Eaton DL, 34:135-72
Edwards G, 33:597-637
Elion GB, 33:1-23
Emmerson KS, 34:91-115
Esbenshade TA, 34:117-33

F

Fan A, 35:341-68
Farley JM, 32:67-88
Farmer SG, 32:511-36
Farrar HC, 31:525-47
Felten DL, 35:417-48
Fenselau C, 32:555-78
Fisher MH, 32:537-53
Fryxell D, 32:579-621
Fukuto JM, 35:165-94
Fulco AJ, 31:177-203
Fung B-K, 33:201-41
Furchgott RF, 35:1-27

G

Gallagher EP, 34:135-72
Galzi J-L, 31:37-72
Gardner P, 35:257-76
Gnegy ME, 33:45-70
Gonzalez FJ, 35:369-90
Grandy DK, 33:281-307
Grasso P, 31:253-87
Guilmette RA, 31:569-601

H

Haffner ME, 31:603-20
Halpern JR, 35:29-53
Hankinson O, 35:307-40
Harden TK, 35:541-79
Harman AW, 35:129-44
Haseman J, 31:621-52
Henrion D, 34:173-90
Herblin WF, 32:135-65
Hersey S, 35:277-305
Hidaka H, 32:377-97
Hieble JP, 33:243-79
Hinson JA, 32:471-510
Hitchings GH, 32:1-6
Hollister LE, 33:165-77

Holsapple MP, 31:73-100
Homeister JW, 34:17-40
Howd R, 35:341-68
Howlett AC, 35:607-34
Hsia SMT, 34:41-67
Hsieh L-L, 34:41-67
Huff J, 31:621-52; 34:343-72
Hughes J, 31:469-501
Hulbert WC, 32:109-34

J

Jackson EK, 31:1-35
Johnson NF, 31:569-601
Jordan VC, 35:195-211

K

Kemp JA, 31:401-25
Kjelsberg MA, 32:167-83
Kobayashi R, 32:377-97
Kopin IJ, 33:467-95
Korzekwa KR, 35:369-90
Krause DN, 31:549-68
Knueger KE, 32:211-37

L

Lake BG, 35:483-507
Laskin DL, 35:655-77
Lazo JS, 35:635-53
Lee HJ, 34:321-41
Lefer AM, 33:71-90
Lefer DJ, 33:71-90
Lefkowitz RJ, 32:167-83
Lester HA, 34:219-49
Levi A, 31:205-28
Lewis JL, 33:383-407
Li B, 32:579-621
Liu LF, 34:191-218
Llinás R, 32:399-421
Lowenthal DT, 32:271-302
Lucchesi BR, 34:17-40
Lucier G, 34:343-72
Ludden T, 32:185-209

M

Macdonald RL, 35:463-82
Madden KS, 35:417-48
Mager S, 34:219-49
Malins DC, 31:371-99
Marton LJ, 35:55-91
Masaki T, 35:235-55

Maxwell MJ, 35:129-44
 McGiff JC, 31:339-69
 Miljanich GP, 35:707-34
 Minneman KP, 34:117-33
 Mirsalis JC, 35:145-64
 Mocchielli I, 32:301-26
 Mohanraj D, 32:579-621
 Mombouli J-V, 35:679-705
 Monforte JA, 35:125-44
 Morris DL, 31:73-100
 Mrozik H, 32:537-53
 Mulder GJ, 32:25-49
 Murray MD, 33:435-65

N

Newton GJ, 31:569-601
 Nicholas RA, 35:541-79
 Nichols AJ, 33:243-79
 Nicotera P, 32:449-70

O

Oguri K, 34:251-79
 Olah ME, 35:581-606
 Oliyai R, 33:521-44
 Olson M, 32:579-621
 Ondetti MA, 34:1-16
 Ostrander GK, 31:371-99
 Ostrowski J, 32:167-83

P

Pang S, 32:623-69
 Papadopoulos V, 32:211-37
 Pechnick RN, 33:353-82
 Pegg AE, 35:55-91
 Pendino KJ, 35:655-77
 Pitt BR, 35:635-53
 Portoghesi PS, 32:239-69
 Preatt V, 31:163-75
 Proud D, 31:129-62

Q

Quick MW, 34:219-49

R

Radić Z, 34:281-320
 Rall DP, 31:621-52
 Ramachandran J, 35:707-34
 Ramakrishnan S, 32:579-621
 Rand MJ, 33:24-44
 Reiffenstein RJ, 32:109-34
 Reinberg AE, 32:51-66
 Reis DJ, 33:309-52
 Revah F, 31:37-72
 Ricaurte GA, 33:639-77
 Richman DD, 33:149-64
 Roberfroid MB, 31:163-75
 Roberts DW, 32:471-510
 Rock DM, 35:463-82
 Rockhold RW, 33:497-520
 Roth SH, 32:109-34
 Ruffolo RR Jr, 33:243-79

S

Sabol KE, 33:639-77
 Sachs G, 35:277-305
 Sanders VM, 35:417-48
 Scarpace PJ, 32:271-99
 Scremin OU, 31:229-51
 Seiden LS, 33:639-77
 Sharratt M, 31:253-87
 Sheiner LB, 32:185-209
 Shin JM, 35:277-305
 Smith RD, 32:135-65
 Smits JFM, 35:501-39
 Snyder NK, 31:73-100
 Snyder SH, 35:213-33
 St-Pierre MV, 32:623-69
 Stadel J M, 33:243-79
 Stanski D, 32:423-47
 Stella VJ, 33:521-44
 Stiles GL, 35:581-606
 Struijker-Boudier HAJ, 35:509-39

T

Takemori AE, 32:239-69

Taylor P, 34:281-320
 Thomas HA, 33:91-108
 Thomassen DG, 31:529-601
 Timmermans PBMWM, 32:135-65
 Tolstoshev P, 33:573-96
 Tritscher A, 34:343-72
 Turner N, 32:271-99

V

Van de Kar LD, 31:289-320
 Vanhoutte PM, 35:679-705

W

Wagner JA, 35:257-76
 Wahlestedt C, 33:309-52
 Wallmark B, 35:277-305
 Wang CC, 35:93-127
 Wei ET, 33:91-108
 Weissmann G, 35:449-62
 Weston AH, 33:597-637
 Winegar RA, 35:145-64
 Wong EHF, 31:401-25
 Wong PC, 32:135-65
 Wood SC, 31:73-100
 Woodruff GN, 31:469-501
 Woosley RL, 31:427-55

X

Xu X, 32:623-69

Y

Yamada H, 34:251-79
 Yamane HK, 33:201-41
 Yeh HC, 31:569-601
 Yoshimura H, 34:251-79

Z

Zhang J, 35:213-33
 Ziegler DM, 33:179-99

CHAPTER TITLES, VOLUMES 31-35

PREFATORY CHAPTERS

Antagonists of Nucleic Acid Derivatives as Medicinal Agents	GH Hitchings	32:1-6
The Quest for a Cure	GB Elion	33:1-23
Adventures in Autopharmacology: A Biographic View with Digressions into Other Matters	MJ Rand	33:24-44
From Peptides to Peptidases: A Chronicle of Drug Discovery	MA Ondetti	34:1-16
A Research Trail Over Half A Century	RF Furchgott	35:1-27

ALLERGY AND DRUG SENSITIVITY

Bradykinin Antagonists	JM Bathon, D Proud	31:129-62
Catecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness	KS Madden, VM Sanders, DL Felten	35:417-48

ANESTHETICS, ANALGESICS, & ANTIINFLAMMATORY AGENTS

Pharmacokinetics and Pharmacodynamics of Anesthetics	D Stanski	32:423-47
Antiinflammatory Peptide Agonists	ET Wei, HA Thomas	33:91-108
Targets for Antiinflammatory Drugs	BN Cronstein, G Weissmann	35:449-62

ANTIMICROBIAL, ANTIVIRAL, AND ANTIPARASITIC CHEMOTHERAPY

The Chemistry and Pharmacology of Avermectins	H Mrozik, MH Fisher	32:537-53
Polyamines as Targets for Therapeutic Intervention	LJ Marton, AE Pegg	35:55-91
Molecular Mechanisms and Therapeutic Approaches to the Treatment of African Trypanosomiasis	CC Wang	35:93-127

AUTONOMIC PHARMACOLOGY

Inhaled Toxicants and Airway Hyperresponsiveness	JM Farley	32:67-88
Pharmacologic and Therapeutic Application of α_2 -Adrenoceptor Subtypes	RR Ruffolo Jr, AJ Nichols, JM Stadel, JP Hieble	33:243-79
α_1 -Adrenergic Receptor Subtypes	KP Minneman, TA Esbenshade	34:117-33

BEHAVIORAL AND PSYCHOPHARMACOLOGY

Geriatric Pharmacology: Basic and Clinical Considerations	DT Lowenthal, PJ Scarpace, N Tumer	32:271-302
New Antidepressants	LE Hollister, JL Claghorn	33:165-77
Cardiovascular Toxicity of Anabolic Steroids	RW Rockhold	33:497-520
Relationships Between Lead-Induced Learning Impairments and Changes in Dopaminergic, Cholinergic, and Glutamergic Neurotransmitter System Functions	DA Cory-Slechta	35:391-415

CANCER CHEMOTHERAPY AND IMMUNOPHARMACOLOGY

2,3,7,8-Tetrachlorodibenzo-p-Dioxin Induced Changes in Immunocompetence: Possible Mechanisms	MP Holsapple, DL Morris, SC Wood, NK Snyder	31:73-100
HIV Drug Resistance	DD Richman	33:149-64

748 CHAPTER TITLES

DNA Topoisomerases: Essential Enzymes and Lethal Targets	AY Chen, LF Liu	34:191-218
The ARYL Hydrocarbon Receptor Complex	Oliver Hankinson	35:307-40
Metallothioneins and Cell Death by Anticancer Drugs	JS Lazo, BR Pitt	35:635-53
CARDIOVASCULAR PHARMACOLOGY		
Functional Architecture of the Nicotinic Acetylcholine Receptor: From the Electric Organ to Brain	J-L Galzi, F Revah, A Bessis, J-P Changeux	31:37-72
Mechanism of Action of Nerve Growth Factor	A Levi, S Alemà	31:205-28
Pharmacological Control of the Cerebral Circulation	OU Scremin	31:229-51
Antiarrhythmic Agents	RL Woosley	31:427-55
Melatonin Receptors	DN Krause, ML Dubocovich	31:549-68
Pharmacology of Nonpeptide Angiotensin II Receptor Antagonists	P Timmermans, AT Chiu, PC Wong, WF Herblin, RD Smith	32:135-65
Pharmacology of the Endothelium in Ischemia-Reperfusion and Circulatory Shock	AM Lefer, DJ Lefer	33:71-90
Complement Activation and Inhibition in Myocardial Ischemia and Reperfusion Injury	JW Homeister, BR Lucchesi	34:17-40
Pharmacology of Cardiac and Vascular Remodeling	HAI Struijker-Boudier, JFM Smits, JGR De Mey	35:509-39
CLINICAL TOXICOLOGY AND DRUG INTERACTIONS		
DRUGS AND RESPIRATION		
ELECTROLYTES AND MINERAL METABOLISM		
Molecular Strategies for Therapy of Cystic Fibrosis	JA Wagner, AC Chao, P Gardner	35:257-76
ENDOCRINE PHARMACOLOGY		
Neuroendocrine Pharmacology of Serotonergic (5-HT) Neurons	LD Van de Kar	31:289-320
Effects of Opioids on the Hypothalamo-Pituitary-Adrenal Axis	RN Pechnick	33:353-82
Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer	VC Jordan	35:195-211
ENVIRONMENTAL AND INDUSTRIAL PHARMACOLOGY AND TOXICOLOGY		
Pharmacokinetic Basis of Age-Related Changes in Sensitivity to Toxicants	LS Birnbaum	31:101-28
Role of Persistent Non-Genotoxic Tissue Damage in Rodent Cancer and its Relevance to Humans	P Grasso, M Sharratt, AJ Cohen	31:253-87
Molecular Mechanisms of Nickel Carcinogenesis	M Costa	31:321-37
Risks from Radon Progeny Exposure: What We Know and What We Need to Know	RA Guilmette, NF Johnson, GJ Newton, DG Thomassen, HC	31:569-601
Scientific Concepts, Value, and Significance of Chemical Carcinogenesis Studies	JE Huff, J Haseman, DP Rall	31:621-52
Hydrogen Sulphide and its Toxicologic Implications	RJ Reiffenstein, SH Roth, WC Hulbert	32:109-34
Respiratory Tract Uptake of Inhalants and Metabolism of Xenobiotics	AR Dahl, JL Lewis	33:383-407
Childhood Lead Poisoning and its Treatment	CR Angle	33:409-33

Carcinogenicity of TCDD: Experimental, Mechanistic, and Epidemiological Evidence	J Huff, G Lucier, A Tritscher	34:343-72
Risk Assessment of Environmental Chemicals	A Fan, R Howd, B Davis	35:341-68
Macrophages and Inflammatory Mediators in Tissue Injury	DL Laskin, KJ Pendino	35:655-77
GASTROINTESTINAL PHARMACOLOGY		
The Pharmacology of the Gastric Acid Pump: The H ⁺ , K ⁺ ATPase	G Sachs, JM Shin, C Briving, B Wallmark, S Hersey	35:277-305
MECHANISMS OF ACTION OF DRUGS AND CHEMICALS		
Mutagenesis of the Beta-2 Adrenergic Receptor: How Structure Elucidates Function	RJ Lefkowitz, J Ostrowski, MA Kjelsberg, MG Caron	32:167-83
Therapeutic Applications of Antisense Agents	ST Crooke	32:329-76
Pharmacology of Protein Kinase Inhibitors	H Hidaka, R Kobayashi	32:377-97
Calcium-Mediated Mechanisms in Chemically Induced Cell Death	S Orrenius, P Nicotera, G Bellomo	32:449-70
Role of Covalent and Noncovalent Interactions in Cell Toxicity: Effects on Proteins	JA Hinson, DW Roberts	32:471-510
Cytotoxic Conjugates Containing Translational Inhibitory Proteins	S Ramakrishnan, D Fryxell, D Mohanraj, M Olson, B Li	32:579-621
Calmodulin in Neurotransmitter and Hormone Action	ME Gnegy	33:45-70
Covalent Modifications of G-Proteins	B-K Fung, HK Yamane	33:201-41
Gene Therapy: Concepts, Current Trials, and Future Directions	P Tolstoshev	33:573-96
Putative Mechanisms of Toxicity of 3-Methylindole: From Free Radical to Pneumotoxicosis	TM Bray, KS Emmerson	34:91-115
Mechanisms of Hepatocarcinogenicity of Peroxisome-Proliferating Drugs and Chemicals	BG Lake	35:483-507
P ₂ -Purine Receptors: Subtype-Associated Signaling Responses and Structure	TK Harden, JL Boyer, RA Nicholas	35:541-79
Pharmacology of Cannabinoid Receptors	AC Howlett	35:607-34
METABOLIC FATE OF DRUGS AND CHEMICALS		
Cytochrome 450 Metabolism of Arachidonic Acid	JC McGiff	31:339-69
Glucuronidation and its Role in Regulation of Biological Activity of Drugs	GJ Mulder	32:25-49
Catalytic Sites of Hemoprotein Peroxidases	PRO de Montellano	32:89-107
Recent Studies on the Structure and Function of Multisubstrate Flavin-Containing Monooxygenases	DM Ziegler	33:179-99
Macromolecular Adducts: Biomarkers for Toxicity and Carcinogenesis	LW Chang, SMT Hsia, P-C Chan, L-L Hsieh	34:41-67
Regiochemistry of Cytochrome P450 Isozymes	K Oguri, H Yamada, H Yoshimura	34:251-79
Structural Basis of Selective Cytochrome P450 Inhibition	JR Halpert	35:29-53
Cytochromes P450 Expression Systems	FJ Gonzalez, KR Korzekwa	35:369-90
MISCELLANEOUS		
Modulation of Hepatocarcinogenesis	MB Roberfroid, N Delzenne, V Pre��t	31:163-75
P450 _{BM-3} and Other Inducible Bacterial P450	AJ Fulco	31:177-203
Cytochromes: Biochemistry and Regulation		
Orphan Products: Origins, Progress, and Prospects	ME Haffner	31:603-20
Concepts in Chronopharmacology	AE Reinberg	32:51-66

750 CHAPTER TITLES

NEUROMUSCULAR PHARMACOLOGY

NEUROPHARMACOLOGY AND NEUROCHEMISTRY

Sites for Antagonism on the N-methyl-D-aspartate Receptor-Channel Complex	EHF Wong, JA Kemp	31:401-25
Cholecystikinin Antagonists	GN Woodruff, J Hughes	31:469-501
Mitochondrial Benzodiazepine Receptors and the Regulation of Steroid Biosynthesis	KE Krueger, V Papadopoulos	32:211-37
The Theoretical Basis for a Pharmacology of Nerve Growth Factor Biosynthesis	I Mocchetti	32:301-26
The Central Role of Voltage-Activated and Receptor-Operated Calcium Channels in Neuronal Cells	M Bertolino, R Llinás	32:399-421
GABA _B Receptor Pharmacology	NG Bowery	33:109-47
Neuropeptide Y-Related Peptides and Their Receptors—Are the Receptors Potential Therapeutic Drug Targets?	C Wahlestedt, DJ Reis	33:309-52
β -Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease	B Cordell	34:69-89
Permeation Properties of Neurotransmitter Transporters	HA Lester, S Mager, MW Quick, JL Corey	34:219-49
The Cholinesterases: From Genes to Proteins	P Taylor, Z Radić	34:281-320
Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition	JM Fukuto, G Chaudhuri	35:165-94
Nitric Oxide in the Nervous System	J Zhang, SH Snyder	35:213-33
Polyamine Regulation of N-Methyl-D-Aspartate Receptor Channels	RL Macdonald, DM Rock	35:463-82
Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation	ME Olah, GL Stiles	35:581-606

PERINATAL AND DEVELOPMENTAL PHARMACOLOGY

Fetal Effects of Maternal Drug Exposure	HC Farrar, JL Blumer	31:525-47
---	----------------------	-----------

PHARMACOKINETICS, DRUG ABSORPTION, AND EXCRETION

Biologically Based Pharmacodynamics Models: Tools for Toxicological Research and Risk Assessment	RB Conolly, ME Andersen	31:503-23
Population Pharmacokinetics/Dynamics	LB Sheiner, T Ludden	32:185-209
Determinants of Metabolite Disposition	S Pang, X Xu, MV St-Pierre	32:623-69
Absorption of Peptide and Peptidomimetic Drugs	GL Amidon, HJ Lee	34:321-41

PHARMACOLOGICALLY ACTIVE NATURAL SUBSTANCES

Adenosine: A Physiological Brake on Renin Release	EK Jackson	31:1-35
Mechanisms of Aflatoxin Carcinogenesis	DL Eaton, EP Gallagher	34:135-72
Antagonists of Neuronal Calcium Channels: Structure, Function, and Therapeutic Implications	GP Miljanich, J Ramachandran	35:707-34

RENAL PHARMACOLOGY

Renal Toxicity of Non-Steroidal Anti-Inflammatory Drugs	MD Murray, DC Brater	33:435-65
--	----------------------	-----------

REPRODUCTION AND FERTILITY

SMOOTH MUSCLE PHARMACOLOGY

Pharmacological Implications of the Flow-Dependence of Vascular Smooth Muscle Tone	JA Bevan, D Henrion	34:173-90
--	---------------------	-----------

Possible Role of Endothelin in Endothelial Regulation of Vascular Tone	T Masaki	35:235-55
Kinins and Endothelial Control of Vascular Smooth Muscle	J-V Mombouli, PM Vanhoutte	35:679-705
STRUCTURE-ACTIVITY RELATIONSHIPS AND MEDICINAL CHEMISTRY		
Selective Naltrexone-Derived Opioid Receptor Antagonists	AE Takemori, PS Portoghese	32:239-69
Biochemical and Molecular Pharmacology of Kinin Receptors	SG Farmer, RM Burch	32:511-36
Molecular Diversity of the Dopamine Receptors	O Civelli, JR Bunzow, DK Grandy	33:281-307
Pharmacology of Parkinson's Disease Therapy: An Update	IJ Kopin	33:467-95
Prodrugs of Peptides and Proteins for Improved Formulation and Delivery	R Oliyai, VJ Stella	33:521-44
Molecular and Ionic Mimicry of Toxic Metals	TW Clarkson	33:545-71
The Pharmacology of ATP-Sensitive Potassium Channels	G Edwards, AH Weston	33:597-637
Amphetamine: Effects on Catecholamine Systems and Behavior	LS Seiden, KE Sabol, GA Ricaurte	33:639-77
TECHNIQUES		
Perspectives in Aquatic Toxicology	DC Malins, GK Ostrand	31:371-99
Systemic Delivery of Polypeptide Drugs through Ocular Route	GCY Chiou	31:457-67
Tandem Mass Spectrometry: The Competitive Edge for Pharmacology	C Fenselau	32:555-78
An Evaluation of the Role of Calcium in Cell Injury	AW Harman, MJ Maxwell	35:129-44
Transgenic Animal Models for Detection of In Vivo Mutations	JC Mirsalis, JA Monforte, RA Winegar	35:145-64



CONTENTS

A RESEARCH TRAIL OVER HALF A CENTURY, <i>Robert F. Furchgott</i>	1
STRUCTURAL BASIS OF SELECTIVE CYTOCHROME P450 INHIBITION, <i>James R. Halpert</i>	29
POLYAMINES AS TARGETS FOR THERAPEUTIC INTERVENTION, <i>Laurence J. Marton and Anthony E. Pegg</i>	55
MOLECULAR MECHANISMS AND THERAPEUTIC APPROACHES TO THE TREATMENT OF AFRICAN TRYPANOSOMIASIS, <i>C. C. Wang</i>	93
AN EVALUATION OF THE ROLE OF CALCIUM IN CELL INJURY, <i>Andrew W. Harman and Michael J. Maxwell</i>	125
TRANSGENIC ANIMAL MODELS FOR DETECTION OF IN VIVO MUTATIONS, <i>Jon C. Mirsalis, Joseph A. Monforte, and Richard A. Winegar</i>	145
INHIBITION OF CONSTITUTIVE AND INDUCIBLE NITRIC OXIDE SYNTHASE: Potential Selective Inhibition, <i>J. M. Fukuto and G. Chaudhuri</i>	165
TAMOXIFEN: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer, <i>V. Craig Jordan</i>	195
NITRIC OXIDE IN THE NERVOUS SYSTEM, <i>J. Zhang and S. H. Snyder</i>	213
POSSIBLE ROLE OF ENDOTHELIN IN ENDOTHELIAL REGULATION OF VASCULAR TONE, <i>Tomoh Masaki</i>	235
MOLECULAR STRATEGIES FOR THERAPY OF CYSTIC FIBROSIS, <i>John A. Wagner, Anthony C. Chao, and Phyllis Gardner</i>	257
THE PHARMACOLOGY OF THE GASTRIC ACID PUMP: The H^+ , K^+ ATPase, <i>George Sachs, Jai Moo Shin, Carin Briving, Bjorn Wallmark, and Steve Hersey</i>	277
THE ARYL HYDROCARBON RECEPTOR COMPLEX, <i>Oliver Hankinson</i>	307
RISK ASSESSMENT OF ENVIRONMENTAL CHEMICALS, <i>A. Fan, R. Howd, and B. Davis</i>	341
CYTOCHROMES P450 EXPRESSION SYSTEMS, <i>Frank J. Gonzalez and Kenneth R. Korzekwa</i>	369

vi CONTENTS (Continued)

RELATIONSHIPS BETWEEN LEAD-INDUCED LEARNING IMPAIRMENTS AND CHANGES IN DOPAMINERGIC, CHOLINERGIC, AND GLUTAMERGIC NEUROTRANSMITTER SYSTEM FUNCTIONS, <i>D. A. Cory-Slechta</i>	391
CATECHOLAMINE INFLUENCES AND SYMPATHETIC NEURAL MODULATION OF IMMUNE RESPONSIVENESS, <i>Kelley S. Madden, Virginia M. Sanders, and David L. Felten</i>	417
TARGETS FOR ANTIINFLAMMATORY DRUGS, <i>Bruce N. Cronstein and Gerald Weissmann</i>	449
POLYAMINE REGULATION OF N-METHYL-D-Aspartate Receptor Channels, <i>Robert L. Macdonald and David M. Rock</i>	463
MECHANISMS OF HEPATOCARCINOGENICITY OF PEROXISOME-PROLIFERATING DRUGS AND CHEMICALS, <i>Brian G. Lake</i>	483
PHARMACOLOGY OF CARDIAC AND VASCULAR REMODELING, <i>Harry A. J. Struijker-Boudier, Jos F. M. Smits, Jo G. R. De Mey</i>	509
P ₂ -PURINERGIC RECEPTORS: Subtype-Associated Signaling Responses and Structure, <i>T. Kendall Harden, José L. Boyer, and Robert A. Nicholas</i>	541
ADENOSINE RECEPTOR SUBTYPES: Characterization and Therapeutic Regulation, <i>Mark E. Olah and Gary L. Stiles</i>	581
PHARMACOLOGY OF CANNABINOID RECEPTORS, <i>Allyn C. Howlett</i>	607
METALLOTHIONENS AND CELL DEATH BY ANTICANCER DRUGS, <i>John S. Lazo and Bruce R. Pitt</i>	635
MACROPHAGES AND INFLAMMATORY MEDIATORS IN TISSUE INJURY, <i>Debra L. Laskin and Kimberly J. Pendino</i>	655
KININS AND ENDOTHELIAL CONTROL OF VASCULAR SMOOTH MUSCLE, <i>Jean-Vivien Mombouli and Paul M. Vanhoutte</i>	679
ANTAGONISTS OF NEURONAL CALCIUM CHANNELS: Structure, Function, and Therapeutic Implications, <i>George P. Miljanich and J. Ramachandran</i>	707
INDEXES	
SUBJECT INDEX	735
CUMULATIVE INDEX OF CONTRIBUTING AUTHORS, VOLUMES 31-35	745
CUMULATIVE INDEX OF TITLES, VOLUMES 31-35	747

